Merus N.V.

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128) for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC), as well as in Phase 1/2 clinical trials for the treatment of non Neuregulin 1. The company is also developing MCLA-158, which is in a phase 1/2 clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 2 clinical trials for the treatment of patients with lungs and other solid tumors; ONO-4685 that is Phase 1/2 clinical trial to treat relapsed/refractory T cell lymphoma; and INCA33890, which is in 1/2 clinical trial phase for advanced solid tumors. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd to commercialize MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to develop trispecific T-cell engaging multi-specific antibody products. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.